FDA MANDATORY PEDIATRIC LABELING RULE WOULD APPLY TO FIRST INDICATION FOR NMEs, MARKETED PRODUCTS WITH WIDE USE OR IMPORTANT BENEFITS IN CHILDREN
Executive Summary
FDA's authority to require pediatric trials prior to approval of an NDA would apply only to the first indication of a new molecular entity or new biological product, an Aug. 15 Federal Register notice states.